Soligenix Reports Positive Safety Review in Phase 3 CTCL Study, Advancing Potential First-Line Treatment

The Data Monitoring Committee for Soligenix Inc. has completed its first safety review of the confirmatory Phase 3 FLASH2 study evaluating HyBryte in patients with cutaneous T-cell lymphoma, concluding the therapy maintains an acceptable safety profile consistent with prior clinical trials. This positive safety assessment represents a critical milestone for the late-stage biopharmaceutical company as it advances HyBryte toward potential regulatory approval and commercialization. The FLASH2 trial builds upon the company's earlier statistically significant Phase 3 results and additional supportive studies that have demonstrated HyBryte's efficacy and tolerability as a potential first-line treatment option for early-stage CTCL patients.

Enrollment in the ongoing Phase 3 study continues to progress according to schedule, with the company expecting to provide further updates in the fourth quarter of 2025. A blinded interim efficacy analysis is planned for the first half of 2026, which will provide additional insights into the therapy's performance without compromising the study's integrity. The successful safety review by the independent Data Monitoring Committee reinforces confidence in HyBryte's development pathway and reduces regulatory risk as the program moves forward. This development is particularly significant given that HyBryte represents a novel photodynamic therapy approach utilizing safe visible light rather than more conventional treatment modalities.

The positive safety findings maintain momentum for HyBryte's potential to address substantial unmet medical needs in the CTCL treatment landscape. Cutaneous T-cell lymphoma represents a rare form of non-Hodgkin lymphoma that primarily affects the skin, and current treatment options often involve significant side effects or limited efficacy. HyBryte's mechanism of action involves synthetic hypericin, which is activated by visible light to target malignant T-cells while minimizing damage to healthy tissue. The therapy's development has been supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority, highlighting its potential importance in addressing rare diseases with limited treatment options.

Soligenix's broader development pipeline includes expansion of synthetic hypericin technology into psoriasis treatment and other inflammatory conditions, as well as vaccine programs targeting various infectious diseases. The company's progress with HyBryte represents a significant step forward in bringing innovative treatments to patients suffering from rare diseases where therapeutic options remain limited. Additional information about the company's development programs and recent updates can be found through their corporate communications channels available at https://ibn.fm/SNGX. The continued advancement of HyBryte through the regulatory process underscores the importance of developing targeted therapies for rare diseases that affect patient populations with limited treatment alternatives.